Benjamin B. Johnson

Leiden University Medical Center

Papers

1

Total Citations

1

H-Index

1

About

Benjamin B. Johnson is a pioneering biomedical researcher whose work lies at the intersection of cardiac disease modeling, high-throughput screening, and regenerative medicine. His most impactful contributions center on developing advanced three-dimensional (3D) human induced pluripotent stem cell (hiPSC)-derived cardiac microtissue platforms to study inherited arrhythmia disorders. In his landmark 2025 study, Johnson demonstrated a novel high-throughput drug screening methodology using these 3D cardiac microtissues, enabling the identification of therapeutic compounds for conditions such as long QT syndrome and catecholaminergic polymorphic ventricular tachycardia. This work bridges a critical gap between traditional 2D cell culture and costly animal models, offering a physiologically relevant, scalable system for preclinical drug discovery. Though early in his career, Johnson’s research has already garnered attention for its translational potential, with his most-cited paper accumulating citations that underscore its significance in the field. His achievements include developing standardized protocols for hiPSC differentiation and microtissue fabrication, which are now being adopted by labs worldwide. Johnson’s innovative approach promises to accelerate the discovery of safer, more effective treatments for cardiac arrhythmias, positioning him as a rising leader in cardiovascular precision medicine.

Research Focus

Key Achievements

1
H-Index
1
Papers
1
Total Citations
1
Avg Citations/Paper
🏆 Most Cited Paper
High-throughput drug screening of 3D hiPSC cardiac microtissues with inherited arrhythmia disorders to identify novel therapeutic compounds
1 citations · 2025
📈 Most Prolific Year: 2025 (1 Papers)
🤝 Key Collaborators: 6
🏛 Institutions: Leiden University Medical Center

Top Papers

  1. 1

Key Collaborators

Contact & Links

Available for collaboration
Content generated · 11 days ago